Zoledronic Acid News and Research

RSS
Zoledronic acid is a drug used to treat patients with hypercalcemia (high blood levels of calcium) caused by cancer. It is also used together with other drugs to treat multiple myeloma and to prevent bone fractures and reduce bone pain in people who have cancer that has spread to the bone. It is a type of bisphosphonate. Also called zoledronate and Zometa.
Bone-strengthening drug zoledronic acid can help fight breast cancer DTCs: Study

Bone-strengthening drug zoledronic acid can help fight breast cancer DTCs: Study

Amgen submits BLA for denosumab subcutaneous RANK Ligand inhibitor

Amgen submits BLA for denosumab subcutaneous RANK Ligand inhibitor

Merrion Pharmaceuticals increases patent protection for Orazol

Merrion Pharmaceuticals increases patent protection for Orazol

RANKL inhibition may prove effective in treatment of human malignancy, suggests study

RANKL inhibition may prove effective in treatment of human malignancy, suggests study

UCSF study: Unusual femur fractures low in patients with osteoporosis

UCSF study: Unusual femur fractures low in patients with osteoporosis

Denosumab exhibits superiority over Zometa in treatment of prostate cancer men with bone metastases

Denosumab exhibits superiority over Zometa in treatment of prostate cancer men with bone metastases

New data suggests bisphosphonate drug may play a role in reducing recurrent breast cancer

New data suggests bisphosphonate drug may play a role in reducing recurrent breast cancer

New data demonstrating the strength of Novartis' hematology portfolio to be presented

New data demonstrating the strength of Novartis' hematology portfolio to be presented

Amgen announces results of Phase 3 head-to-head trial evaluating denosumab versus Zometa

Amgen announces results of Phase 3 head-to-head trial evaluating denosumab versus Zometa

Amgen announces results of Phase 3 trial in the treatment of bone metastases

Amgen announces results of Phase 3 trial in the treatment of bone metastases

Amgen to present its four Phase 3 clinical trial results

Amgen to present its four Phase 3 clinical trial results

Zoledronic acid may save lives by strengthening immune system

Zoledronic acid may save lives by strengthening immune system

FDA approves Reclast (zoledronic acid) for osteoporosis in postmenopausal women

FDA approves Reclast (zoledronic acid) for osteoporosis in postmenopausal women

Zometa (zoledronic acid) shown to enhance chemotherapy in reducing breast tumor size

Zometa (zoledronic acid) shown to enhance chemotherapy in reducing breast tumor size

Bisphosphonates for osteoporosis increase risk for heart problems

Bisphosphonates for osteoporosis increase risk for heart problems

Benefits of combined treatments against cancer

Benefits of combined treatments against cancer

Cheap drug combo stops breast cancer in its tracks

Cheap drug combo stops breast cancer in its tracks

Effectiveness and risks of six bisphosphonates for osteoporosis

Effectiveness and risks of six bisphosphonates for osteoporosis

Once a year osteoporosis jab reduces fractures and saves lives

Once a year osteoporosis jab reduces fractures and saves lives

Once a year treatment for osteoporosis now available in the U.S.

Once a year treatment for osteoporosis now available in the U.S.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.